Please use this identifier to cite or link to this item:
Title: DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
Author: Hidalgo-Tenorio, Carmen
Vinuesa, David
Plata, Antonio
Martín-Dávila, Pilar
Iftimie, Simona
Sequera, Sergio
Loeches, Belén
Lopez-Cortés, Luis Eduardo
Fariñas, Mari Carmen
Fernández-Roldan, Concepción
Javier-Martinez, Rosario
Muñoz, Patricia
Arenas-Miras, Maria del Mar
Martínez-Marcos, Francisco Javier
Miró Meda, José M.
Herrero, Carmen
Bereciartua, Elena
De, Jesus, Samantha E.
Pasquau, Juan
Keywords: Endocarditis
Issue Date: 19-Oct-2019
Publisher: BioMed Central
Abstract: Objectives: To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. Methods: A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. Results: Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20 ) and 557 days for IE (283,187.45 ). Conclusions: DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug.
Note: Reproducció del document publicat a:
It is part of: Annals of Clinical Microbiology and Antimicrobials, 2019, vol. 18, p. 30
Related resource:
ISSN: 1476-0711
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
693671.pdf909.92 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons